Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival

Cherif, H.; Bacha, S.; Habibech, S.; Racil, H.; Cheikhrouhou, S.; Chaouech, N.; Chabbou, A.; Megdiche, M.L.

doi:10.1183/13993003.congress-2016.pa4841

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite recent therapeutic advancements (e.g., molecularly targeted therapeutics and immune checkpoint inhibitors), the therapeutic efficacy of novel agents has been limited to only small percentages of patients who harbor specific biomarkers or genetic alterations, leaving the majority of NSCLC patients with poor prognosis and a high mortality rate [ 31 , 32 , 33 , 34 ]. Hence, novel therapeutic approaches are urgently needed to extend clinical benefits to a broader patient population and improve patient outcomes in advanced NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

Kim

Doherty

Moghe

et al. 2022

Cancers

View full text Add to dashboard Cite

Because lung cancer remains the most common and lethal of cancers, novel therapeutic approaches are urgently needed. RB94 is a truncated form of retinoblastoma tumor suppressor protein with elevated anti-tumor efficacy. Our investigational nanomedicine (termed scL-RB94) is a tumor-targeted liposomal formulation of a plasmid containing the gene encoding RB94. In this research, we studied anti-tumor and immune modulation activities of scL-RB94 nanocomplex in preclinical models of human non-small cell lung cancer (NSCLC). Systemic treatment with scL-RB94 of mice bearing human NSCLC tumors significantly inhibited tumor growth by lowering proliferation and increasing apoptosis of tumor cells in vivo. scL-RB94 treatment also boosted anti-tumor immune responses by upregulating immune recognition molecules and recruiting innate immune cells such as natural killer (NK) cells. Antibody-mediated depletion of NK cells blunted the anti-tumor activity of scL-RB94, suggesting that NK cells were crucial for the observed anti-tumor activity in these xenograft models. Treatment with scL-RB94 also altered the polarization of tumor-associated macrophages by reducing immune-suppressive M2 macrophages to lower immune suppression in the tumor microenvironment. Collectively, our data suggest that the efficacy of scL-RB94 against NSCLC is due to an induction of tumor cell death as well as enhancement of innate anti-tumor immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

Kim

Doherty

Moghe

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…However, the systemic toxicity caused by many chemotherapeutic drugs remains one of the most challenging issues for cancer therapy, resulting in poor quality of life for cancer patients (Cherif et al, ; Hurria et al, ; Zou et al, ). Additionally, most anticancer drugs show unfavorable pharmaceutical and pharmacological properties such as poor aqueous solubility (Lu, Liong, Zink, & Tamanoi, ; Narvekar, Xue, Eoh, & Wong, ), lack of stability (Chae et al, ; Jackson, Rafiq, & Brentjens, ), rapid metabolism in body (Wang et al, ), irritating nature (Nagata et al, ), and multidrug resistance after repeated exposure (Tian et al, ; Wu, Yang, Nie, Shi, & Fan, ).…”

Section: Introductionmentioning

confidence: 99%

Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy

Qiao

Wan

Zhou

et al. 2018

WIREs Nanomed Nanobiotechnol

259

137

View full text Add to dashboard Cite

Cancer remains one of the world's leading causes of death. However, most conventional chemotherapeutic drugs only show a narrow therapeutic window in patients because of their inability to discriminate cancer cells from healthy cells. Nanoparticle-based therapeutics (termed nanotherapeutics) have emerged as potential solutions to mitigate many obstacles posed by these free drugs. Deep insights into knowledge of the tumor microenvironment and materials science make it possible to construct nanotherapeutics that are able to release cargoes in response to a variety of internal stimuli and external triggers. Therefore, such highly sophisticated nanosystems could help impede the premature release of toxic drugs in the blood circulation or healthy tissues, thus enhancing the safety profiles of encapsulated drugs. In this context, this review offers a comprehensive overview of several specific stimuli, including internal stimuli (e.g., pH, temperature, enzyme, redox, and H O ) and external stimuli (e.g., magnetic, photo, and ultrasound). We envision that applications of these smart nanotherapeutics can benefit cancer patients and provide a good chance for clinical translation of many nanoparticle formulas. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > Diagnostic Nanodevices Diagnostic Tools > in vitro Nanoparticle-Based Sensing.

show abstract

“… 9 , 10 Furthermore, lower QoL and depressed mood are associated with shorter survival among patients. 11 - 14 Therefore, effective interventions to prevent the decline of QoL in patients undergoing chemotherapy are critically needed.…”

Section: Introductionmentioning

confidence: 99%

Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non–Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial

Liu

Mao

et al. 2020

Integr Cancer Ther

View full text Add to dashboard Cite

Background: Cancer patients often experience decreased quality of life during chemotherapy. This study aimed to determine the preliminary efficacy and safety of Reishi & Privet Formula (RPF) for maintaining quality of life among patients with non–small cell lung cancer (NSCLC) undergoing chemotherapy. Methods: We conducted a phase II randomized, double-blind, placebo-controlled clinical trial in China. Adults with NSCLC scheduled to receive chemotherapy were randomly assigned (3:1 ratio) to receive oral RPF (3.36 g/day) or placebo daily for 6 weeks. The main outcome was the Functional Assessment of Cancer Therapy–Lung (FACT-L). We evaluated RPF’s safety profile using the Common Terminology Criteria for Adverse Events and assessed changes in outcome measures from baseline to weeks 3 and 6 using a linear mixed effects model. Results: We enrolled 82 participants across 8 cancer centers in China. The median age was 59 years, 56 (68%) had advanced cancer. Compared with the placebo group, the RPF group had nonstatistically significant higher quality of life as measured by the FACT-L total score ( P = .086) over 2 cycles of chemotherapy. The RPF group was associated with a nonsignificant better general health ( P = .050) and emotional well-being ( P = .090) than the placebo group. Adverse events rates did not differ between groups. Conclusions: This study demonstrated preliminary safety and suggests a promising trend in RPF’s effect on maintaining quality of life and emotional well-being among NSCLC patients undergoing chemotherapy. Future adequately powered randomized-controlled trials are needed to verify the efficacy and safety of RPF in cancer patients undergoing chemotherapy.

show abstract

Chemotherapy toxicity in advanced non-small cell lung cancer and its impact on survival

Cited by 5 publications

References 0 publications

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

Stimuli‐responsive nanotherapeutics for precision drug delivery and cancer therapy

Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non–Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial

Contact Info

Product

Resources

About